In this article, we will be looking at the 5 best medical stocks under $10. If you want to see our detailed analysis and outlook of the medical industry, go directly to the 10 Best Medical Stocks Under $10.
5. DBV Technologies S.A. (NASDAQ: DBVT)
Number of Hedge Fund Holders: 7
Stock Price as of July 23rd: $5.36
DBV Technologies S.A. (NASDAQ: DBVT) ranks 5th on the 10 best medical stocks under $10. The biopharmaceutical firm based in France develops immunotherapies for food allergies. DBV Technologies S.A. (NASDAQ: DBVT) makes immunology products such as Viaskin for peanut allergy in children ages 4 to 11, which received FDA Fast Track and Breakthrough Therapy designation in 2015, and Viaskin for cow’s milk protein allergy in patients 2 to 17 years old, which received FDA Fast Track designation in 2016.
On May 4th, Societe Generale analyst Delphine Le Louet upgraded DBV Technologies S.A. (NASDAQ: DBVT) to Hold from Sell with a price target of €11 per share. The stock has gained 29% in the past year and 105% year to date.
The company has a market cap of $606 million. In the first quarter of 2021, DBV Technologies S.A. (NASDAQ: DBVT) had an EPS of -$0.26, beating estimates by $0.34. In the first quarter, the company’s revenue was $2.94 million, a decrease of 37.7%, but beats revenue estimates by $1.54 million. At the end of the first quarter, DBV Technologies S.A. (NASDAQ: DBVT) had cash of $152.5 million.
At the end of the first quarter of 2021, 7 hedge funds in the database of Insider Monkey held stakes worth $128 million in DBV Technologies S.A. (NASDAQ: DBVT). Baker Bros. Advisors is the company’s largest shareholder, with 14.6 million shares, worth $77,894,000.
4. Endo International plc (NASDAQ: ENDP)
Number of Hedge Fund Holders: 17
Stock Price as of July 23rd: $5
Endo International plc (NASDAQ: ENDP) ranks 4th on the 10 best medical stocks under $10. The Dublin-based pharmaceutical company markets branded and generic pain, endocrinology, urology, and orthopedic medications. Endo International plc (NASDAQ: ENDP) also sells cancer and transplantation pharmaceutical products.
Endo International plc (NASDAQ: ENDP) has soared 41% in the last five days after settling a $35 million opioid dispute in Tennessee. Before the opioid trial, Citi analyst Navann Ty maintained a Buy rating on Endo International plc (NASDAQ: ENDP) with a price target of $11 per share.
The company has a market cap of $1.17 billion. In the first quarter of 2021, Endo International plc (NASDAQ: ENDP) had an EPS of $0.73, beating estimates by $0.26. The company’s first-quarter revenue came in at $717.92 million, beating revenue estimates by $49.39 million. Shares of Endo International plc (NASDAQ: ENDP) increased 52% in the last twelve months.
There were 17 hedge funds that reported owning stakes in Endo International plc (NASDAQ: ENDP) at the end of the first quarter, up from 13 funds a quarter earlier. The total value of these stakes at the end of Q1 is $406 million.
3. Amneal Pharmaceuticals, Inc. (NYSE: AMRX)
Number of Hedge Fund Holders: 15
Stock Price as of July 23rd: $4.83
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ranks 3rd on the list of 10 best medical stocks under $10. The New Jersey-based drugmaker sells generic medicines across the US. The pharmaceutical company was founded in 2002 and was formerly known as Atlas Holdings, Inc.
In April, Guggenheim analyst Dana Flanders maintained a Buy rating on Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and increased the firm’s price target to $8 per share from $6.50 previously. The analyst commented that the recently launched generic medicine Ortho Evra and the demand of NuvaRing are the primary drivers in meeting the company’s fiscal year 2021 financial target.
Shares of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) surged 8% pre-market on June 8th after the FDA agreed to evaluate the Biologics License Application (BLA) Bevacizumab for metastatic colorectal cancer therapy. Meanwhile, the stock has gained 12.1% in the last five days after the FDA approved the generic version of the ophthalmic product TobraDex.
The company has a market cap of $718 million. In the first quarter of 2021, Amneal Pharmaceuticals, Inc. (NYSE: AMRX) had an EPS of $0.20, beating estimates by $0.02. Due to lower influenza activity in the first quarter of 2021, the company’s revenue declined 1% to $493 million, down from $499 million in the first quarter of 2020.
There were 15 hedge funds that reported owning stakes in Amneal Pharmaceuticals, Inc. (NYSE: AMRX) at the end of the first quarter, up from 8 funds a quarter earlier. The total value of these stakes at the end of Q1 is $77.5 million.
2. SOC Telemed, Inc. (NASDAQ: TLMD)
Number of Hedge Fund Holders: 12
Stock Price as of July 23rd: $4.76
SOC Telemed, Inc. (NASDAQ: TLMD) ranks 2nd on the list of 10 best medicine stocks under $10. The Virginia-based medical company provides telemedicine technology and services to hospitals, government institutions, and other healthcare groups. SOC Telemed, Inc. (NASDAQ: TLMD) offers various telehealth services in the fields of cardiology, neurology, pulmonology, psychiatry, and critical care.
On May 28th, Baird analyst Vikram Kesavabhotla maintained an Outperform rating on SOC Telemed, Inc. (NASDAQ: TLMD) and increased the price target to $8 per share from $7.50 previously. According to the analyst, SOC Telemed, Inc. (NASDAQ: TLMD) is ahead of its peers in the telehealth sector because it is exposed to the high-growth industry of critical care. The stock has gained 6.3% in the last five days.
The company has a market cap of $475 million. The company’s first-quarter revenue was consistent with $14.8 million in the same period in 2020. SOC Telemed, Inc. (NASDAQ: TLMD) had $32.5 million of cash at the end of the first quarter, up from $5 million in the same quarter in 2020.
By the end of the first quarter of 2021, 12 hedge funds out of the 866 tracked by Insider Monkey held stakes in SOC Telemed, Inc. (NASDAQ: TLMD), worth roughly $54 million. This is compared to 13 hedge funds in the previous quarter with stakes worth approximately $88 million.
1. Accuray Incorporated (NASDAQ: ARAY)
Number of Hedge Fund Holders: 17
Stock Price as of July 23rd: $4.19
Topping the 10 best medical stocks under $10 is medical device manufacturer Accuray Incorporated (NASDAQ: ARAY). The California-based medical device firm sells radiation therapy instruments that treat intracranial, breast, prostate, lung, and head and neck tumors.
Northland analyst Jason Wittes started coverage of Accuray Incorporated (NASDAQ: ARAY) with an Outperform rating and a $7 per share price target in January, highlighting the company’s efficient R&D effort. Accuray Incorporated (NASDAQ: ARAY) was also given a Buy rating by BTIG, with a $9 price target. The stock has gained 90% in the last twelve months. Shares of ARAY also increased 4% in the previous five days.
The company has a market cap of $378 million. In the third quarter of 2021, Accuray Incorporated (NASDAQ: ARAY) had an EPS of $0.00, beating estimates by $0.01. The company’s third-quarter revenue was $102.6 million, increasing 3% year over year and beating estimates by $3.29 million.
At the end of the first quarter of 2021, 17 hedge funds in the database of Insider Monkey held stakes worth $90.1 million in Accuray Incorporated (NASDAQ: ARAY). Archon Capital Management is the company’s largest shareholder, with 4.5 million shares worth $22.6 million.
You can also take a peek at the 15 Best Consumer Discretionary Stocks to Buy Now and 15 Best Cybersecurity Stocks to Buy Now.
